Novo Nordisk's acquisition journey is driven by price pressure and a hunger for innovation

Acquisitions have been par for the course at Novo Nordisk in recent years. The pharmaceutical company has entered into a long list of collaboration deals and partnerships, which CEO Lars Fruergaard Jørgensen tells MedWatch is intended to lead to more innovation and treatments – and is a trend he expects to continue.

Lars Fruergaard Jørgensen, CEO of Novo Nordisk | Photo: Asger Ladefoged/Ritzau Scanpix

Home is where the heart is, as the old saying goes. But in the Danish suburb of Bagsværd, some 12 kilometers northwest of Copenhagen, Denmark’s biggest pharmaceutical company Novo Nordisk is showing signs that it holds a different view.

The soon-to-be centenarian pharmaceutical firm has completed large, billion-dollar acquisitions in a hunt for more growth, and has entered partnerships and strategic collaboration with external parties.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today